$10.0m recently raised to expedite product development.

Henslow acted as Lead Manager to raise $10m for Hemideina. The capital raised will be used to fund product development in preparation for first in human studies. Founded in 2017 by Dr Kate Lomas and Dr Liz Williams, Hemideina aims to replicate normal human hearing more closely using their proprietary mechanical signal processing technology. Taking inspiration from nature, Hemideina’s approach to solving the challenge of severe-to-profound hearing loss will enable improved hearing quality, improved device utility and also provide aesthetic benefits for users.

Bio-inspired solutions for a limitless world of hearing.

In an established market currently serviced by 3 major players with similar products, Hemideina is set to disrupt the Cochlear Implant (CI) market through proprietary mechanical signal processing. The company aims to solve the technical, lifestyle, usability & cost drawbacks of current CI technology.

The Highlights

  • US$2.0bn

    Global market worth

  • 2%

    market penetration by incumbent major players

  • 1 in 10 by 2050

    Affected by disabling hearing loss worldwide (WHO)

A trusted source of innovation for those with hearing loss

Hemideina aims to revolutionize hearing through proprietary mechanical signal processing. Henslow has assisted Hemideina with fund raising since 2018. We are proud to support Hemideina on their mission to positively impact the lives of people with severe-to-profound hearing loss.


October 2018

Early Stage - $580,000

October 2019

Series A - $4,000,000

October 2020

Placement - $10,000,000

I’d like to extend my thanks to the team at Henslow for managing the raise, as well as our team – the high-calibre work completed to date has built confidence around our technology with investors and continues to be the key to our success.

Dr Elizabeth Williams, CEO & Co-Founder of Hemideina